Rukhsana Ahmad, MD
Psychiatry · Roswell, GANPI 1164507679
Payments from drug & device makers
Across 419 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$951
- AbbVie$925
- Supernus Pharmaceuticals, Inc.$913
- Otsuka America Pharmaceutical, Inc.$596
- Johnson & Johnson$574
- Axsome Therapeutics, Inc.$537
- plus $4K from 24 others
What the payments were for
- Food & beverage$8,15299%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $951 |
| AbbVie(2 entities) | 49 | $925 |
| Supernus Pharmaceuticals, Inc. | 42 | $913 |
| Otsuka America Pharmaceutical, Inc. | 32 | $596 |
| Johnson & Johnson | 29 | $574 |
| Axsome Therapeutics, Inc. | 23 | $537 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $499 |
| Ironshore Pharmaceuticals Inc. | 25 | $460 |
| Lundbeck LLC | 25 | $442 |
| Corium, LLC | 19 | $387 |
| Neos Therapeutics, LP | 18 | $277 |
| Neuronetics, Inc. | 3 | $217 |
| Teva Pharmaceuticals USA, Inc. | 9 | $203 |
| Almatica Pharma LLC | 10 | $193 |
| Tris Pharma Inc | 7 | $148 |
| Vanda Pharmaceuticals Inc. | 8 | $145 |
| Alkermes, Inc. | 6 | $135 |
| Bausch Health US, LLC | 6 | $102 |
| Collegium Pharmaceutical, Inc. | 5 | $102 |
| Noven Therapeutics, LLC | 4 | $74 |
| Shire North American Group Inc | 4 | $64 |
| Vertical Pharmaceuticals, LLC | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Brainsway USA Inc | 1 | $29 |
| Tempus AI, Inc | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY$155
- QELBREE$111
How this compares
$8,199 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $32,732 |
| Invega SustennaPaliperidone Palmitate | 11 | $24,730 |
| Aripiprazole | 76 | $18,558 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,115 |
| Quetiapine Fumarate | 169 | $2,757 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $2,450 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 51 | $2,208 |
| Atomoxetine Hcl | 14 | $1,403 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,343 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 90 | $1,246 |
| Bupropion XlBupropion Hcl | 38 | $1,199 |
| Duloxetine Hcl | 68 | $1,016 |
| Ziprasidone Hcl | 12 | $985 |
| Clozapine | 11 | $944 |
| Risperidone | 116 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $596 | $32,73213 claims |
| Johnson & JohnsonInvega Sustenna | $574 | $24,73011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $499 | $4,11511 claims |
| Almatica Pharma LLCSertraline Hcl | $193 | $32563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Michael RosenRoswell$141K
- Richard WinerRoswell$103K
- Joel KirsonRoswell$99K
- Alexandra DoddRoswell$54K
- Scot BayRoswell$26K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.